GGrantIndex
← Search

Cancer Center Administration

$100,000P30FY2020CANIH

Fred Hutchinson Cancer Research Center, Seattle WA

Investigators

Linked publications, trials & patents

Trial NCT06995898Trial NCT06682039Trial NCT06484595Trial NCT06193070Trial NCT05947500Trial NCT05930496Trial NCT05183828Trial NCT04902144Trial NCT04751383Trial NCT04682301Trial NCT04667481Trial NCT04660331Trial NCT04539366Trial NCT04505553Trial NCT04502524Trial NCT04500548Trial NCT04496219Trial NCT04489719Trial NCT04472338Trial NCT04466475Trial NCT04447313Trial NCT04444232Trial NCT04442581Trial NCT04431479Trial NCT04410900Trial NCT04387227Trial NCT04384692Trial NCT04383743Trial NCT04375631Trial NCT04372927Trial NCT04370301Trial NCT04359784Trial NCT04336943Trial NCT04329065Trial NCT04282187Trial NCT04260776Trial NCT04257578Trial NCT04254133Trial NCT04231877Trial NCT04220229Trial NCT04211766Trial NCT04208724Trial NCT04205409Trial NCT04200482Trial NCT04198922Trial NCT04196010Trial NCT04195945Trial NCT04195633Trial NCT04194918Trial NCT04188912Trial NCT04175431Trial NCT04156828Trial NCT04155840Trial NCT04151940Trial NCT04120246Trial NCT04111497Trial NCT04083183Trial NCT04083170Trial NCT04081779Trial NCT04081298Trial NCT04062955Trial NCT04060849Trial NCT03999515Trial NCT03991884Trial NCT03986502Trial NCT03980769Trial NCT03970096Trial NCT03907527Trial NCT03891784Trial NCT03864419Trial NCT03807063Trial NCT03806192Trial NCT03781778Trial NCT03779867Trial NCT03779854Trial NCT03778021Trial NCT03776864Trial NCT03749460Trial NCT03747484Trial NCT03737955Trial NCT03723863Trial NCT03718338Trial NCT03672981Trial NCT03670966Trial NCT03670069Trial NCT03660930Trial NCT03649841Trial NCT03641287Trial NCT03606486Trial NCT03602898Trial NCT03600038Trial NCT03585231Trial NCT03574012Trial NCT03570476Trial NCT03531918Trial NCT03525106Trial NCT03523195Trial NCT03522584Trial NCT03518242Trial NCT03516812

Abstract

PROJECT SUMMARY: ADMINISTRATION The Consortium Administration provides high quality, efficient, and effective support to Fred Hutch/University of Washington Cancer Consortium leaders, Research Programs, Shared Resources, and members. Administration owns and drives the processes that Consortium scientific leaders use to define the Consortium's vision and strategic goals, implement initiatives, monitor progress in achieving objectives, and secure needed resources to develop and maintain the requisite infrastructure. Consortium Director Dr. Gary Gilliland and senior leaders developed a strategic plan through a process started when he arrived in 2015. The process is ongoing by design with annual internal and external evaluations of milestones. Throughout the process Administration ensures that CCSG guidelines are integral to the strategic goals and activities. As a result of these activities, Consortium membership has grown by >170 members; cancer-relevant grant funding for the Consortium is at $242M, of which $50M is from the NCI; interventional trials have 5,424 accruals and non-interventional trials have 5,292 accruals (increases of 83% and 20%, respectively, from FY 2014 to FY 2018); and members have over 6,600 cancer-related publications as authors and co-authors, with 11% of them in journals with impact factors greater than 20. New in this cycle of the CCSG are the components for Community Outreach & Engagement (COE) and Cancer Research Career Enhancement (CRCE). Administration has been pivotal to establishing offices for both of these new components to oversee their respective areas of activity. Other new Consortium initiatives include the formation of three Integrated Research Centers (IRCs), the continued development of the Seattle Translational Tumor Research initiative (STTR), and major enhancements of clinical trials infrastructure. Administration has interfaced with initiative leaders and their respective administrators in order to leverage strengths and resources toward supporting Research Programs and members. Finally, as a result of faculty feedback, a new developing Shared Resource for preclinical mouse models was developed by Administration to further Consortium science. `

View original record on NIH RePORTER →